This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
H. Lundbeck A/S
Drug Names(s): Lu 02-750
Description: Lu 02-750 is a dopaminergic agent acting on brain areas affected in Parkinson's disease. In animal models, the compound has demonstrated convincing effects as compared to conventional treatments.
The precise mechanism of LU 02-750 has not been released, but Axon has patents on aporphine prodrugs (to avoid the first-pass metabolism of apomorphine) and also prodrugs with dopamine agonist, partial agonist, inverse agonist and/or antagonist effects, with mention of autoreceptors and D3 receptors.
Deal Structure: Lu 02-750 was discovered in collaboration with Groningen University and Axon Biochemicals. In September 2004, Axon Biochemicals and Lundbeck signed a collaboration agreement giving Lundbeck access to Axon's IPR on dopaminergic compounds with potential in the treatment of CNS disorders.
Partners: Axon Biochemicals B.V.
Lu 02-750 News
Pink Sheet Weekly Trademark Review April 29, 2014
Additional information available to subscribers only: